State Street Corp Reduces Holdings in Achillion Pharmaceuticals, Inc. (ACHN)

State Street Corp trimmed its holdings in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 7.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,974,429 shares of the biopharmaceutical company’s stock after selling 342,787 shares during the period. State Street Corp owned 2.91% of Achillion Pharmaceuticals worth $18,243,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of ACHN. Janus Henderson Group PLC acquired a new stake in shares of Achillion Pharmaceuticals during the second quarter worth $20,778,000. Dimensional Fund Advisors LP raised its holdings in shares of Achillion Pharmaceuticals by 204.9% during the second quarter. Dimensional Fund Advisors LP now owns 1,868,968 shares of the biopharmaceutical company’s stock worth $8,579,000 after purchasing an additional 1,255,962 shares during the period. Senzar Asset Management LLC acquired a new stake in shares of Achillion Pharmaceuticals during the second quarter worth $4,966,000. Vanguard Group Inc. raised its holdings in shares of Achillion Pharmaceuticals by 7.2% during the first quarter. Vanguard Group Inc. now owns 9,585,823 shares of the biopharmaceutical company’s stock worth $40,357,000 after purchasing an additional 646,415 shares during the period. Finally, Teachers Advisors LLC raised its holdings in shares of Achillion Pharmaceuticals by 42.9% during the first quarter. Teachers Advisors LLC now owns 1,347,858 shares of the biopharmaceutical company’s stock worth $5,674,000 after purchasing an additional 404,317 shares during the period. 74.81% of the stock is currently owned by institutional investors.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) opened at $3.43 on Friday. Achillion Pharmaceuticals, Inc. has a 12-month low of $2.95 and a 12-month high of $5.66.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. During the same quarter in the prior year, the business posted ($0.15) EPS. analysts anticipate that Achillion Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

WARNING: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/19/state-street-corp-reduces-holdings-in-achillion-pharmaceuticals-inc-achn.html.

A number of analysts have weighed in on ACHN shares. Ladenburg Thalmann Financial Services dropped their target price on shares of Achillion Pharmaceuticals from $9.00 to $6.50 and set a “buy” rating on the stock in a report on Tuesday, September 12th. Zacks Investment Research raised shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, September 14th. Chardan Capital dropped their target price on shares of Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating on the stock in a report on Wednesday, August 9th. Robert W. Baird reissued a “neutral” rating and set a $4.00 target price (down from $5.00) on shares of Achillion Pharmaceuticals in a report on Tuesday, September 12th. Finally, BidaskClub cut shares of Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. Achillion Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $5.29.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply